Impaired postprandial skeletal muscle vascular responses to a mixed meal challenge in normoglycaemic people with a parent with type 2 diabetes by Russell, Ryan D. et al.
University of Texas Rio Grande Valley 
ScholarWorks @ UTRGV 
Health & Human Performance Faculty 
Publications and Presentations College of Health Professions 
9-29-2021 
Impaired postprandial skeletal muscle vascular responses to a 
mixed meal challenge in normoglycaemic people with a parent 
with type 2 diabetes 
Ryan D. Russell 
The University of Texas Rio Grande Valley, ryan.russell@utrgv.edu 
Katherine M. Roberts-Thomson 
Donghua Hu 
Timothy Greenaway 
Andrew C. Betik 
See next page for additional authors 
Follow this and additional works at: https://scholarworks.utrgv.edu/hhp_fac 
 Part of the Diseases Commons 
Recommended Citation 
Russell, R. D., Roberts-Thomson, K. M., Hu, D., Greenaway, T., Betik, A. C., Parker, L., Sharman, J. E., 
Richards, S. M., Rattigan, S., Premilovac, D., Wadley, G. D., & Keske, M. A. (2021). Impaired postprandial 
skeletal muscle vascular responses to a mixed meal challenge in normoglycaemic people with a parent 
with type 2 diabetes. Diabetologia, 10.1007/s00125-021-05572-7. Advance online publication. 
https://doi.org/10.1007/s00125-021-05572-7 
This Article is brought to you for free and open access by the College of Health Professions at ScholarWorks @ 
UTRGV. It has been accepted for inclusion in Health & Human Performance Faculty Publications and Presentations 
by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact 
justin.white@utrgv.edu, william.flores01@utrgv.edu. 
Authors 
Ryan D. Russell, Katherine M. Roberts-Thomson, Donghua Hu, Timothy Greenaway, Andrew C. Betik, 
Lewan Parker, James E. Sharman, Stephen M. Richards, Stephen Rattigan, Dino Premilovac, Glenn D. 
Wadley, and Michelle A. Keske 




Impaired postprandial skeletal muscle vascular responses to a mixed meal 
challenge in normoglycaemic people with a parent with type 2 diabetes  
Ryan D. Russell1,2, Katherine Roberts-Thomson 3, Donghua Hu 1, Timothy Greenaway 4, 
Andrew C. Betik 3,5, Lewan Parker 3,5, James E. Sharman 1, Stephen M. Richards 4, Stephen 
Rattigan 1, Dino Premilovac 4, Glenn D. Wadley 3 and Michelle A. Keske 1,3,5 
 
Ryan D. Russell and Katherine Roberts-Thomson are joint first authors. 
 
1 Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia 
2 Department of Health and Human Performance, College of Health Professions, University 
of Texas Rio Grande Valley, Brownsville, TX, USA 
3 Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition 
Sciences, Deakin University, Geelong, VIC, Australia  
4 Tasmanian School of Medicine, University of Tasmania, Hobart, TAS, Australia 
5 Baker Heart and Diabetes Institute, Melbourne, VIC, Australia 
Corresponding author: Michelle A. Keske 
E-mail: Michelle.Keske@deakin.edu.au 
ORCID identifiers:  
RD Russell: 0000-0002-1275-1472 
K Roberts-Thomson: 0000-0002-0950-4972 
D Hu: 0000-0003-2654-5212 
T Greenaway: 0000-0001-5871-3917 
AC Betik: 0000-0001-8294-9719 
L Parker: 0000-0002-5372-1851 
JE Sharman: 0000-0003-2792-0811 
SM Richards: 0000-0002-5988-0423  
2 
 
S Rattigan: 0000-0001-6172-3040 
D Premilovac: 0000-0003-2770-4713 
GD Wadley: 0000-0002-6617-4359 
MA Keske: 0000-0003-4214-7628 
 
Tweet A clinical study led by @KeskeMichelle shows that adult offspring from parents with 
type 2 diabetes have poor muscle vascular health, even if they have normal blood sugar 
levels.  #T2D #SkeletalMuscle @DeakinIPAN @DeakinResearch @TasSchoolMed 
 
 




Aims/hypothesis Microvascular blood flow (MBF) increases in skeletal muscle postprandially 
to aid in glucose delivery and uptake in muscle. This vascular action is impaired in individuals 
who are obese or have type 2 diabetes. Whether MBF is impaired in normoglycaemic people 
at risk of type 2 diabetes is unknown. We aimed to determine whether apparently healthy 
people at risk of type 2 diabetes display impaired skeletal muscle microvascular responses to a 
mixed-nutrient meal.  
Methods In this cross-sectional study, participants with no family history of type 2 diabetes 
(FH−) for two generations (n=18), participants with positive family history of type 2 diabetes 
(FH+; i.e. a parent with type 2 diabetes; n=16) and those with type 2 diabetes (n=12) underwent 
a mixed meal challenge (MMC). Metabolic responses (blood glucose, plasma insulin and 
indirect calorimetry) were measured before and during the MMC. Skeletal muscle large artery 
haemodynamics (2D and Doppler ultrasound, and Mobil-O-graph) and microvascular 
responses (contrast-enhanced ultrasound) were measured at baseline and 1 h post MMC.  
Results Despite normal blood glucose concentrations, FH+ individuals displayed impaired 
metabolic flexibility (reduced ability to switch from fat to carbohydrate oxidation vs FH−; 
p<0.05) during the MMC. The MMC increased forearm muscle microvascular blood volume 
in both the FH− (1.3-fold, p<0.01) and FH+ (1.3-fold, p<0.05) groups but not in participants 
with type 2 diabetes. However, the MMC increased MBF (1.9-fold, p<0.01), brachial artery 
diameter (1.1-fold, p<0.01) and brachial artery blood flow (1.7-fold, p<0.001) and reduced 
vascular resistance (0.7-fold, p<0.001) only in FH− participants, with these changes being 
absent in FH+ and type 2 diabetes. Participants with type 2 diabetes displayed significantly 
higher vascular stiffness (p<0.001) compared with those in the FH− and FH+ groups, however,  
vascular stiffness did not change during the MMC in any participant group. 
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Conclusions/interpretation Normoglycaemic FH+ participants display impaired postprandial 
skeletal muscle macro- and microvascular responses, suggesting that poor vascular responses 
to a meal may contribute to their increased risk of type 2 diabetes. We conclude that vascular 
insulin resistance may be an early precursor to type 2 diabetes in humans, which can be 
revealed using a MMC.   
















AI Acoustic intensity 
β Microvascular flow velocity 
CEU Contrast-enhanced ultrasound 
eNOS  Endothelial nitric oxide synthase 
FH− No family history of type 2 diabetes 
FH+ Positive family history of type 2 diabetes 
MBF Microvascular blood flow 
MBV Microvascular blood volume 
MMC Mixed meal challenge 
NOS Nitric oxide synthase 




Research in context  
What is already known about this subject?  
• People with a positive family history of type 2 diabetes (FH+; i.e. a first degree relative 
with type 2 diabetes) are at higher risk of developing type 2 diabetes than the general 
population 
• FH+ people often have insulin resistance, with skeletal muscle being identified as a 
primary contributor 
• The metabolic consequences of being FH+ are well established, however, the vascular 
outcomes in this at risk population are not known 
What is the key question?  
• Do apparently healthy people with a parent with type 2 diabetes have impaired 
postprandial skeletal muscle vascular responses? 
What are the new findings?  
• Despite having normal blood glucose concentrations, FH+ individuals had impaired 
forearm muscle macro- and microvascular blood flow responses to a mixed meal 
challenge (MMC) similar to those with type 2 diabetes  
• Impaired vascular reactivity is an early feature of being FH+, which is identifiable via 
a MMC 
How might this impact on clinical practice in the foreseeable future?  
• Vascular insulin resistance is a key feature of FH+ and may serve as a new therapeutic 




Despite new knowledge and advancements in medical care, the incidence of type 2 diabetes 
continues to rise along with its vascular complications [1]. The pathogenesis of type 2 diabetes 
is multifaceted, with insulin resistance recognised as an early feature in the development and 
progression of type 2 diabetes [2]. Having the capacity to identify insulin resistance early on 
in groups at risk of type 2 diabetes will provide insight into the early pathophysiology of type 
2 diabetes and its complications, allowing targeted work using appropriate interventions. 
It is well established that people with a first degree relative with type 2 diabetes are at higher 
risk of developing the disorder, with rates two- to sixfold greater than those without a family 
history [3]. Even in the presence of normal blood glucose levels, people with a positive family 
history of type 2 diabetes (FH+) often display whole-body insulin resistance [4], with skeletal 
muscle insulin resistance identified as a major contributor [5, 6]. We have reported that 
normoglycaemic FH+ adults have impaired metabolic flexibility to an oral glucose challenge 
(reduced ability to alter substrate oxidation postprandially)  similar to those with established 
type 2 diabetes [7]. Although the metabolic consequences of FH+ are well established, the 
vascular outcomes in this at risk population are unknown. 
Skeletal muscle is an important tissue for postprandial glucose disposal [8, 9]. Blood flow in 
skeletal muscle, in particular the microvasculature, plays an important role in this process [10-
15]. Physiological hyperinsulinaemia elicited by a hyperinsulinaemic–euglycaemic clamp or 
mixed meal challenge (MMC) stimulates both total-limb and microvascular blood flow (MBF) 
in the skeletal muscle of healthy humans [10-12]. Increased postprandial MBF is key for the 
delivery of glucose and insulin to myocytes [10-12]. Blunted skeletal muscle microvascular 
responses to insulin have been demonstrated in animal models of insulin resistance [13, 14] 
and type 2 diabetes [15], and in obese insulin resistant humans via insulin infusion and 
following a MMC [10, 12]. This phenomenon is known as ‘microvascular insulin resistance’ 
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and occurs early in the development of insulin resistance in animal models [13, 14, 16], 
representing a role in the pathogenesis of type 2 diabetes. However, whether this microvascular 
pathology is present in apparently healthy ‘at risk’ humans is yet to be determined.  
Therefore, the purpose of this study was to determine whether microvascular responses are 
impaired in apparently healthy people at risk for type 2 diabetes, and whether this could be 
revealed using a MMC. We assessed skeletal muscle micro- and macrovascular responses in 
normoglycaemic FH+ individuals, and compared their responses with both healthy people with 
no family history of type 2 diabetes (FH−), and those with clinically diagnosed type 2 diabetes. 
It was hypothesised that the MMC would reveal step-wise impairments in muscle MBF across 




Participants and screening This study was conducted at two sites and approved by the 
University of Tasmania and Deakin University Human Research Ethics Committees. All 
participants provided written informed consent. This study was conducted in accordance with 
the Declaration of Helsinki as revised in 2008, and procedures followed were in accordance 
with university guidelines.  
Based on a priori power calculation, it was determined that 16 participants would be required 
to see a 30% difference in postprandial MBF in the healthy groups (α = 0.05, power = 80%). 
Eighteen healthy people with no family history of type 2 diabetes for two generations (neither 
parents nor grandparents with type 2 diabetes, FH−) and 16 healthy people with at least one 
parent with type 2 diabetes (FH+) completed the study. An additional 12 people with clinically 
diagnosed type 2 diabetes completed the study. Recruitment was done via community and 
university advertisement. Participants were included in the study if they were between 18 and 
70 years old, had a BMI >19 kg/m2, and were stable weight for the past 3 months. Participants 
were excluded if they had a history of smoking, a clinical history of cardiovascular disease, 
myocardial infarction, stroke, uncontrolled BP (seated brachial BP >160/100 mmHg), 
pulmonary disease, peripheral artery disease, arthritis, skeletal muscle disease, severe liver 
disease or malignancy within the past 5 years. All participants attended a screening visit at the 
research facility, completed a medical questionnaire, and had height, weight and BP measured 
to determine eligibility. Participants also completed the International Physical Activity 
Questionnaire [17]. Participants were recruited and tested between August 2014 and October 
2019. The study was a non-blinded, single-arm study, where participants completed a MMC. 
Body composition Body composition was assessed using dual-energy x-ray absorptiometry 
(DEXA) (Lunar iDXA, GE Healthcare, Australia/New Zealand at Deakin University; Hologic 
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Delphi densitometer, USA at the University of Tasmania). Total and trunk body fat were 
determined for all participants.  
Clinic visits Participants arrived at the testing facility after an overnight fast and having 
refrained from strenuous exercise and alcohol consumption for 48 h. Medications for type 2 
diabetes were stopped for 48 h prior to testing. Participants lay supine while a cannula was 
placed in the antecubital vein of the left arm for blood sampling and infusion of a contrast 
agent.  
MMC A liquid MMC comprising 1254kJ (53% carbohydrate, 29% protein and 15% fat) was 
given to the participants and was consumed within a 5 min time period. Blood was sampled 
every 15-30 min over 2 h following ingestion of the meal. Blood glucose and plasma insulin 
AUC were both calculated using the trapezoidal rule.  
Blood analysis Fasting glucose, HbA1c, total cholesterol, triacylglycerol, HDL-cholesterol and 
LDL-cholesterol were measured at an accredited pathology laboratory (Australian Clinical 
Labs, Australia for the Deakin University site; Royal Hobart Hospital, Australia for the 
University of Tasmania site). Blood glucose was measured by an automated analyser (ABL800 
FLEX blood gas analyser, Radiometer Medical, Denmark at the Deakin University site; Yellow 
Springs Instruments, USA at the University of Tasmania site), and plasma insulin measured 
using an enzyme-linked immunosorbent assay (ALPCO, Salem, NH, USA). 
Indirect calorimetry for assessment of metabolic flexibility Participants wore a silicon 
facemask attached to a metabolic cart (Quark RMR Cosmed, Italy for the Deakin University 
site; MasterScreen CPX, CareFusion, Germany for the University of Tasmania site) for 20 min 
at baseline and for 55 min following ingestion of the MMC to collect and analyse expired gases. 
The metabolic cart was calibrated using room air and a gas mixture of a known O2 and CO2 
concentration before each clinical testing visit. Breath-by-breath data were collected and 
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analysed in 5 min blocks from which the respiratory exchange ratio (RER) was determined. 
Metabolic flexibility was calculated as the change in RER (from baseline) AUC (∆ RER AUC).  
Skeletal muscle MBF Contrast-enhanced ultrasound (CEU) was used to determine 
microvascular responses of the right forearm flexor group. An L9-3 linear array transducer 
interfaced to an ultrasound machine was used (iU22; Philips Healthcare, Australia – same for 
both sites). Microbubbles (1.5 ml, Definity, Lantheus Medical Imaging, Australia) were diluted 
into 30 ml of saline (154 mmol/l NaCl) and continuously infused intravenously for CEU 
imaging. Microbubbles were infused at 120-160 ml/hr (based on participant’s body weight and 
degree of tissue opacification). Once the systemic concentration of microbubbles reached 
steady state (~5 min), a high-energy pulse of ultrasound (mechanical index 1.3) was transmitted 
to destroy microbubbles in the selected region of imaging (deep flexor muscle group). Rate of 
reperfusion (mechanical index 0.11 for continuous imaging) into the microvasculature of the 
muscle was measured in real time at baseline and repeated 60 min following the MMC. 
Microbubble infusion, gain, depth and focus were optimised for each participant and kept 
identical between baseline and 60 min measurements. The arterial concentration of 
microbubbles was determined by imaging the brachial artery at a submaximal concentration 
(30 ml/h) and used to correct for any changes in blood pool concentration of microbubbles 
between participants.  
Images were background subtracted to eliminate signal from larger blood vessels that had 
greater velocities and tissue per se. Background-subtracted acoustic intensity (AI) vs time was 
fitted to the following equation: y = A(1-e-β(t – tb)), where y is AI at time t, tb is background time 
(0.5 s), A is AI at the plateau of the curve (a measure of microvascular blood volume [MBV]), 
β is the time κ (a measure of microvascular refilling rate) and e is Euler's number. MBF was 
determined by A×β. An example of an ultrasound image and its corresponding curve fit has 
been provided (electronic supplementary material [ESM] Fig. 1). 
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Brachial and large artery haemodynamics Brachial artery measures were taken ~5-10 cm 
proximal to the antecubital fold with an L12-5 linear array transducer. Brachial artery 
diameter was measured in triplicate using 2D imaging of the longitudinal artery. Velocity was 
determined using pulse wave Doppler, measured by automated tracing software, and the 
values averaged over approximately 10-12 heartbeats. Diameter and velocity values were 
used to determine brachial artery blood flow at baseline and 60 min post-ingestion of the 
MMC.  
All participants were fitted with a Mobil-O-Graph monitor (IEM, Germany), validated to 
estimate central and brachial BP, vascular stiffness and augmentation index [18]. Central aortic 
pulse wave velocity was also estimated using this device by analysis of oscillometric brachial 
cuff waveforms [19]. Readings were taken at baseline and at 60 min post-ingestion of the 
MMC. Augmentation index was calculated from the central pressure waveform and normalised 
to a heart rate of 75 beats per min (bpm). Since augmentation index is associated with height, 
we also indexed this variable to the participant’s height. Forearm vascular resistance was 
calculated by dividing mean arterial pressure (mmHg) by total brachial arterial blood flow 
(ml/min).   
Statistical methods Data are presented as the means ± SEM after testing for normality using 
the Kolmogorov–Smirnov test. Continuous measurements in tables are also expressed as a 
median and IQR. Categorical variables in tables are reported as numbers and percentages. A 
one-way ANOVA was used to compare differences between groups. For categorical variables, 
a Fisher’s exact test was performed. Comparisons of multiple means were examined using a 
two-way repeated measures ANOVA (group × time) followed by a Student–Neuman–Keuls 
post hoc test. Planned contrast analysis of the baseline and postprandial time points were 
conducted using a Student–Neuman–Keuls test if there was a main effect for group or time. If 
data were not normally distributed, the data were log transformed for analysis only. If data 
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were missing, the participant for that particular measurement was omitted. Statistics were 
performed using SigmaPlot (Systat Software, USA). A value of p<0.05 was considered as 
statistically significant.  
 
Results 
Participants Of the 53 participants screened, three were not eligible, two were lost to follow-
up and two dropped out, resulting in 46 participants completing the study. The participants who 
were not eligible included one FH− participant who was underweight (BMI <19kg/m2), one 
individual with type 2 diabetes but normal fasting blood glucose and HbA1c levels, and one 
individual with type 2 diabetes with a previous reaction to Definity contrast agent. Two 
participants were lost to follow-up (one FH+ and one with type 2 diabetes) and two dropped 
out (one FH− and one FH+) due to difficulties with venous cannulation. Equipment 
malfunction resulted in loss of participant data for metabolic flexibility (one FH−), CEU (one 
FH−), brachial artery (one FH−) and vascular resistance and stiffness (one FH− and one FH+). 
Participant characteristics Blood analysis and anthropometric characteristics are summarised 
in Table 1. FH− and FH+ participants had similar age, fasting clinical chemistries (blood 
glucose, HbA1c, plasma insulin, plasma lipids), HOMA-IR, QUICKI and BMI. FH+ 
individuals had greater total body (%) and trunk fat (%) than FH− individuals.  
As expected, people with type 2 diabetes displayed greater body weight, BMI, fasting glucose, 
HbA1c, plasma insulin, HOMA-IR and triacylglycerol and lower QUICKI than FH− and FH+ 
individuals. In addition, people with type 2 diabetes had elevated central systolic BP (cSBP), 
total body (%) and trunk fat (%) (Table 1) and medication use (ESM Table 1) compared with 
FH− and FH+ participants. Self-reported physical activity levels (moderate and vigorous 
combined) were not statistically different between groups (Table 1). 
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Metabolic responses to the MMC Blood glucose levels increased over time in all groups 
following the MMC (Fig. 1a). The 2 h glucose AUC following the MMC was significantly 
greater (p<0.001) in participants with type 2 diabetes compared with FH− and FH+ (Fig. 1b), 
whereas the AUC did not differ between FH− and FH+ (Fig. 1b).  
Plasma insulin levels increased over time in all groups in response to the MMC (Fig. 1c). There 
was a significant interaction (group × time, p=0.006) for the plasma insulin time course; 
however, the post hoc did not reveal any significant differences at any time point between 
groups. The insulin 2 h AUC was not different between groups (Fig. 1d). 
RER increased from baseline in response to the MMC in the FH− and FH+ groups but not in 
the type 2 diabetes group (Fig. 1e). There was a significant interaction (group × time, p=0.002) 
for the RER time course; however, the post hoc did not reveal any significant differences at 
any time point between groups. Metabolic flexibility (Δ RER AUC) was significantly blunted 
in both type 2 diabetes and the FH+ groups compared with the FH− group in response to the 
MMC (Fig. 1f).  
Skeletal muscle microvascular responses to the MMC Forearm MBV increased 
significantly from baseline in response to the MMC in both FH− (p<0.01) and FH+ (p<0.05) 
groups; however, this response was absent in the type 2 diabetes group (Fig. 2a). Skeletal 
muscle β (microvascular flow velocity) did not change in response to the MMC and did not 
differ between groups (Fig. 2b). The FH− group had a significantly elevated (p<0.01) forearm 
muscle MBF response to the MMC (Fig. 2c), which was blunted in both FH+ and type 2 
diabetes. FH+ participants had a significantly lower % change in postprandial MBF (but not 
MBV or β individually) compared with FH− participants (ESM Fig. 2). 
Brachial artery responses to the MMC Brachial artery diameter increased significantly in 
FH− participants (p<0.01) in response to the MMC; however, no changes were observed in the 
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FH+ and type 2 diabetes groups (Fig. 3a). Brachial artery flow velocity did not change in 
response to the MMC and did not differ between groups (Fig. 3b). Brachial artery blood flow 
increased in response to the MMC in FH− (p<0.001), but not FH+ or type 2 diabetes 
participants (Fig. 3c).  
Vascular resistance and stiffness Resting forearm vascular resistance (mean arterial BP 
divided by brachial blood flow) was not different between groups; however, the FH− group 
had a significant decrease (p<0.001) post-MMC which was absent in the FH+ and type 2 
diabetes groups (Fig. 4a). FH+ individuals had significantly greater forearm vascular resistance 
than FH− following the MMC (p<0.05) (Fig. 4a).  
Pulse wave velocity (vascular stiffness) did not change in response to the MMC across any of 
the participant groups (Fig. 4b). However, participants with type 2 diabetes had higher pulse 
wave velocity at rest and following the MMC than both FH− (p<0.001) and FH+ (p<0.001) 
groups (Fig. 4b).  
Augmentation index was not different at baseline and did not change in response to the MMC 
across any of the participant groups (Fig. 4c).  
Exploratory analyses Our study was not designed or powered to assess impact of sex, body 
composition and phase of menstrual cycle on outcomes. We have performed an exploratory 
analysis to address these confounders by excluding all female participants and those male 
participants with very low body fat (<15%) and show that when FH− and FH+ male participants 
had similar height, weight, BMI and % body fat, FH+ participants still display an impairment 






Our study demonstrates for the first time that otherwise healthy FH+ people display impaired 
vascular haemodynamic responses to a mixed-nutrient meal. These findings are important as 
vascular responses to meal ingestion, in particular increased muscle MBF, are critical for 
prevention of cardiometabolic disease. We conclude that vascular impairments may be an early 
precursor to type 2 diabetes in humans, which can be revealed in the postprandial state 
following mixed meal ingestion.  
Skeletal muscle is an important tissue for postprandial glucose disposal [8, 9]. Skeletal muscle 
glucose uptake and utilisation occur via a combination of an increase in blood glucose 
concentration (mass action effect), and a rise in endogenous insulin levels enhancing glucose 
uptake into tissues from the bloodstream [8]. Regulation of muscle blood flow by insulin is an 
important physiological process as it controls the rate of glucose and insulin delivery to the 
myocyte [20, 21]. In skeletal muscle of healthy people, physiological hyperinsulinaemia, either 
during a hyperinsulinaemic–euglycaemic clamp or elicited via mixed meal ingestion, 
stimulates both total-limb blood flow (macrovascular blood flow) and MBF [10-12]. Blunted 
skeletal muscle microvascular responses to insulin have been demonstrated in animal models 
of insulin resistance [13, 14] and type 2 diabetes [15]. The impaired microvascular responses 
to insulin contribute to muscle insulin resistance and occur before defects in large artery 
haemodynamics [13, 14]. Using animal models, others have demonstrated that microvascular 
insulin resistance occurs early (3 days following high fat feeding) and precedes whole-body 
insulin resistance (7 days) and impairments in large artery vasodilation to acetylcholine (28 
days) in rats [22]. Here we extend these findings and demonstrate an impaired MBF response 
in apparently healthy (normoglycaemic) FH+ individuals in response to a MMC. 
  
It is well established that FH+ individuals are at higher risk of developing type 2 diabetes than 
those without a family history of diabetes [3]. In particular, FH+ people often display skeletal 
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muscle insulin resistance as a major contributor of disease progression [5, 6]. The blunted 
metabolic flexibility in our FH+ group indicates altered whole-body metabolism in these 
people, despite normal postprandial blood glucose and plasma insulin levels when compared 
with FH− individuals. Normoglycaemic FH+ individuals are reported to have impaired 
metabolic flexibility in response to oral glucose loading [7]. We observed similar impairments 
in metabolic flexibility in FH+ individuals when using a more physiologically relevant 
postprandial challenge containing fat and protein, which are not present in pure glucose loads 
[7]. We cannot ascertain the fate of glucose after the MMC without the addition of isotopic 
tracers, measures of muscle glucose disposal and glycogen content. However, metabolic 
flexibility is positively associated with whole-body glucose disposal (r=0.65, p<0.0001) [23]. 
In the present study, we present novel findings to suggest that loss of skeletal muscle 
microvascular insulin sensitivity alongside impaired metabolic flexibility may occur before the 
development of whole-body insulin resistance. This finding is in agreement and adds 
mechanistic rationale to other studies showing impaired forearm muscle glucose uptake in FH+ 
individuals during a MMC [24].  
In our study, MBF impairment in the FH+ group was observed despite MBV (capillary 
recruitment) increasing to a similar extent as in the FH− group, highlighting that dilation of 
pre-capillary arterioles remain intact in our cohort of FH+ (but not in type 2 diabetes), in the 
postprandial state. Insulin (hyperinsulinaemic–euglycaemic clamp) increases MBV in skeletal 
muscle in rats and humans which positively influences glucose disposal [25-27]. Other studies 
demonstrate that velocity influences insulin-stimulated glucose disposal (their experimental 
paradigm does not allow for insulin to increase MBV due to full capillary recruitment in their 
experimental model) [28]. As such, there is a growing body of evidence that both volume and 
velocity and, therefore, MBF are important for glucose disposal in skeletal muscle. 
Improvements in MBF after exercise training in people with type 2 diabetes are intimately 
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linked with improved glucose regulation [29]. This suggests that the flow velocity within the 
microcirculation plays an important role in influencing MBF following a MMC.  
Postprandial brachial artery dilation (measured as vessel diameter) and blood flow was 
increased in FH−, but absent in people with FH+ and type 2 diabetes. These data may indicate 
endothelial dysfunction in FH+, which can manifest early on and is sustained across the type 2 
diabetes continuum. In support, other studies have shown that FH+ individuals have impaired 
large artery endothelial function as assessed by endothelial-mediated vasodilators or flow-
mediated dilation [4, 30-32]. Our findings of impaired brachial artery responses are consistent 
with other data showing similar impairments in forearm muscle blood flow in the postprandial 
state in FH+ individuals and those with type 2 diabetes [24]. Lambadiari et al demonstrated 
that the macrovascular impairment influenced postprandial glucose disposal (with forearm 
muscle blood flow positively correlating with muscle glucose disposal) [24]. However, that 
study did not assess skeletal muscle specific MBF which is important because it is the 
microvasculature that controls glucose and insulin delivery to the myocyte [20, 25, 33, 34] 
because not all vasodilators that augment large artery blood flow concomitantly increase 
glucose disposal to muscle. Methacholine and sodium nitroprusside can each increase large 
artery blood flow but can have opposing effects on muscle insulin-mediated glucose disposal 
[35, 36]. Large artery blood flow can be separated from flow changes within the 
microcirculation. For example, vasodilation with methacholine during a hyperinsulinaemic–
euglycaemic clamp in rats augments insulin-mediated microvascular perfusion and muscle 
glucose uptake, whereas a similar degree of vasodilation with bradykinin has the opposite 
effect [37]. Adrenaline (epinephrine) stimulates total-limb blood flow without altering muscle 
microvascular perfusion [38, 39] providing further evidence that measuring large artery blood 
flow does not always dictate changes at the microvascular level. 
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Although the mechanism for postprandial-mediated vasodilation is not yet fully understood, it 
has been consistently shown that insulin (hyperinsulinaemic–euglycaemic clamp) stimulates 
brachial artery blood flow and MBF via a nitric oxide synthase (NOS)-dependent process [25, 
40, 41] with endothelial NOS (eNOS) being the major isoform [16, 42]. Postprandial 
endothelial dysfunction can be restored with L-arginine supplementation (a precursor to nitric 
oxide) in overweight individuals low in L-arginine [43] suggesting that ingestion of food 
stimulates blood flow via a NOS-dependent process. Cultured endothelial cells taken from 
umbilical cords of healthy FH+ newborns have impaired expression of eNOS and low rates of 
nitric oxide synthesis [44]. Therefore, it is perhaps not surprising that FH+ individuals, even 
those who are apparently healthy, have impaired postprandial stimulated macrovascular blood 
flow and MBF. However, further work linking NOS defects with poor postprandial muscle 
MBF needs to be performed. 
In support of previous research, the type 2 diabetes group displayed higher BP and vascular 
stiffness (higher pulse wave velocity) than FH− and FH+ groups [45]. However, we did not 
observe any differences in vascular stiffness between FH− and FH+ groups which is in contrast 
to others who have demonstrated greater vascular stiffness in FH+ [46, 47]. These major 
differences are likely due to previous studies recruiting cohorts of FH+ with a more advanced 
form of insulin resistance (higher HOMA-IR and/or higher insulin secretion to a postprandial 
challenge). Despite normal BP and vascular compliance, we demonstrate that FH+ individuals 
have impaired brachial blood flow and forearm vascular resistance compared with FH−. This 
may indicate that the development of arterial stiffness (which is likely to reflect structural 
changes to the circulatory system) takes place after the establishment of endothelial 
dysfunction, and that these structural vascular derangements are distinct in the pathogenesis of 
insulin resistance and type 2 diabetes.  
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Several limitations are acknowledged in this study. First, the participants with type 2 diabetes 
were older than those in the FH− and FH+ groups. However, the primary aim of the study was 
to compare the metabolic and vascular responses in age-matched FH− and FH+ individuals, 
whereas the type 2 diabetes group was recruited as a negative control. Therefore, recruiting a 
younger cohort of participants with type 2 diabetes would not have impacted the main findings 
or conclusions of the study. Second, although healthy FH− and FH+ participants were matched 
for BMI, the FH+ group had significantly greater amounts of total and truncal body fat, which 
may contribute to their vascular insulin resistance. We also acknowledge the FH+ group had a 
greater proportion of female participants than the FH− group. However, our exploratory 
analysis (ESM Table 2) showed that sex and differences in body composition between the FH− 
and FH+ groups did not impact on the outcomes or the overall interpretation of the current 
study. Understanding why FH+ individuals have impaired postprandial skeletal muscle 
vascular actions is important to follow-up. 
Conclusion Postprandial vascular insulin resistance is an early pathophysiological feature of 
insulin resistance even in the presence of normoglycaemia. A loss of vascular responsiveness 
(in particular MBF) that manifests after each meal in people with insulin resistance may be a 
mechanism that, over time, contributes to worsening of insulin resistance, hyperglycaemia and 
type 2 diabetes development. Correcting this microvascular defect may be an early intervention 
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Table 1 Participant characteristics 
Characteristic 
 
FH−  FH+  Type 2 diabetes   
Sex, male/female  13/5 8/8 7/5 
Age, years     
  Mean ± SEM  40 ± 4 39 ± 3 56 ± 2§,¶ 
  Median (IQR) 41 (25–57) 40 (31–47) 58 (53–60) 
Diabetes duration, years    
  Mean ± SEM  – – 8 ± 1 
  Median (IQR) – – 8 (4–12) 
Height, cm    
  Mean ± SEM  176 ± 2 167 ± 3§ 168 ± 2§ 
  Median (IQR) 179 (167–183) 168 (159–176) 169 (160–176) 
Weight, kg    
  Mean ± SEM  76.5 ± 2.5 72.7 ± 3.2 89.3 ± 5.2§,¶ 
  Median (IQR) 74.2 (69.6–87.6) 76.5 (64.3–81.1) 90.5 (74.3–108.0) 
BMI, kg/m2    
  Mean ± SEM  24.7 ± 0.7 25.9 ± 0.8 31.6 ± 1.6§,¶ 
  Median (IQR) 24.6 (22.4–26.1) 25.9 (24.0–28.3) 31.6 (26.6–34.5) 
Total fat, %    
  Mean ± SEM  22.8 ± 2.0 30.7 ± 1.8§ 33.3 ± 2.8§ 
  Median (IQR) 20.2 (16.4–28.1) 30.3 (24.6–35.4) 32.4 (25.6–40.7) 
Trunk fat, %    
  Mean ± SEM  22.5 ± 1.9 30.9 ± 1.9§ 36.1 ± 2.6§ 
  Median (IQR) 21.2 (16.5–29.4) 30.8 (24.3–35.9) 36.1 (29.2–45.4) 
Physical activity, h/weeka    
  Mean ± SEM  7.0 ± 1.0 4.2 ± 1.5 4.4 ± 1.9 
  Median (IQR) 8.1 (3.9–9.9) 2.7 (1.4–5.4) 1.7 (0.0–7.8) 
Fasting glucose, mmol/l    
  Mean ± SEM  4.7 ± 0.1 4.6 ± 0.2 10.1 ± 10.9§,¶ 
  Median (IQR) 4.7 (4.3–5.0) 4.8 (4.2–5.1) 9.9 (7.2–12.4) 
HbA1c, mmol/mol    
  Mean ± SEM  35 ± 1 34 ± 1 63 ± 5§,¶ 
  Median (IQR) 34 (32–37) 34 (31–37) 58 (52–69) 
HbA1c, %    
  Mean ± SEM  5.3 ± 0.1 5.3 ± 0.1 7.9 ± 0.5§,¶ 
  Median (IQR) 5.3 (5.1–5.5) 5.3 (5.0–5.5) 7.5 (6.9–8.5) 
Fasting insulin, pmol/l    
  Mean ± SEM  36.4 ± 3.2 39.6 ± 4.6 67.9 ± 12.2§,¶ 
  Median (IQR) 36.9 (24.2–46.8) 37.5 (25.0–48.4) 56.3 (32.3–104.2) 
Fasting total cholesterol, mmol/l    
  Mean ± SEM  4.7 ± 0.3 5.0 ± 0.2 4.6 ± 0.3 
  Median (IQR) 4.4 (3.8–5.3) 5.0 (4.3–5.8) 4.3 (3.7–5.6) 






aPhysical activity data missing for n=6 FH− and n=2 type 2 diabetes participants 
§p<0.05 vs FH−; ¶p<0.05 vs FH+   
 




  Mean ± SEM  1.5 ± 0.1 1.4 ± 0.1 1.3 ± 0.1  
  Median (IQR) 1.6 (1.3–1.9) 1.4 (1.1–1.8) 1.1 (1.0–1.4) 
Fasting LDL-cholesterol, mmol/l    
  Mean ± SEM  2.8 ± 0.3 3.1 ± 0.2 2.8 ± 0.4 
  Median (IQR) 2.8 (1.7–3.5) 3.4 (2.7–3.7) 2.4 (2.1–3.3) 
Fasting triacylglycerol, mmol/l    
  Mean ± SEM  0.7 ± 0.1 0.9 ± 0.1 1.9 ± 0.4§,¶ 
  Median (IQR) 0.7 (0.5–0.8) 1.0 (0.6–1.2) 1.6 (1.2–2.2) 
HOMA-IR    
  Mean ± SEM  1.1 ± 0.1 1.2 ± 0.1 4.6 ± 1.0§,¶ 
  Median (IQR) 1.1 (0.8–1.4) 1.2 (0.9–1.4) 3.7 (1.9–5.9) 
QUICKI    
  Mean ± SEM  0.39 ± 0.01 0.38 ± 0.01 0.32 ± 0.01§,¶ 
  Median (IQR) 0.38 (0.36–0.40) 0.37 (0.36–0.39) 0.32 (0.30–0.35) 
SBP, mmHg    
  Mean ± SEM  125 ± 3 118 ± 2 133 ± 4¶  
  Median (IQR) 125 (114–138) 117 (111–122) 134 (126–142) 
DBP, mmHg    
  Mean ± SEM  78 ± 2 76 ± 1 85 ± 3¶  
  Median (IQR) 78 (71–87) 76 (73–79) 85 (81–96) 
cSBP, mmHg    
  Mean ± SEM  116 ± 3 108 ± 2§ 126 ± 3§,¶ 
  Median (IQR) 116 (109–125) 108 (106–112) 125 (117–133) 
cDBP, mmHg    
  Mean ± SEM  80 ± 2 77 ± 1 86 ± 3¶  




Fig. 1 Metabolic effects of the MMC. Metabolic effects in FH− (blue), FH+ (purple) and 
type 2 diabetes (T2D; red) participants. (a) The 2 h blood glucose concentrations and (b) blood 
glucose AUC for MMC are shown. (c) The  2 h plasma insulin concentrations and (d) plasma 
insulin AUC for MMC are shown. (e) Changes in RER and (f) metabolic flexibility, expressed 
as the AUC for the change in RER from baseline in response to a MMC. Data are expressed as 
mean ± SEM with individual data points. *p<0.05 vs 0 min for FH−; †p<0.05 vs 0 min for 
FH+; ‡p<0.05 vs 0 min for T2D; ‡‡p<0.05 T2D vs FH− and FH+ at each time point; §p<0.05 
vs FH−; ¶p<0.05 vs FH+ 
Fig. 2 Skeletal muscle microvascular responses to the MMC. Skeletal muscle microvascular 
haemodynamics at rest (0 min) and in response to a MMC (60 min) in FH− (blue), FH+ (purple) 
and type 2 diabetes (T2D; red) participants. Forearm muscle (a) MBV, (b) β  and (c) MBF. 
Data expressed as mean ± SEM with individual data points. *p<0.05, **p<0.01 vs 0 min 
Fig. 3 Brachial artery responses to the MMC. Skeletal muscle brachial artery haemodynamics 
at rest (0 min) and in response to a MMC (60 min) in FH− (blue), FH+ (purple) and type 2 
diabetes (T2D; red) participants. Brachial artery (a) diameter, (b) flow velocity  and (c) blood 
flow. Data expressed as mean ± SEM with individual data points. **p<0.01, ***p<0.001 vs 0 
min 
Fig. 4 Vascular resistance and stiffness responses to the MMC. Forearm vascular resistance 
and stiffness at rest (0 min) and in response to a MMC (60 min) in FH− (blue), FH+ (purple) 
and type 2 diabetes (T2D; red) participants. (a) Forearm vascular resistance, (b) pulse wave 
velocity and (c) augmentation index, adjusted to a heart rate of 75 beats per min (bpm) and 
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participants’ height. Data expressed as mean ± SEM with individual data points. ***p<0.001 
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